Abstracts tagged "Health policy"

Abstract Number: 2480 • ACR Convergence 2023
Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Victoria Konzett¹, Andreas Kerschbaumer², Josef S Smolen³, Eirik Kristianslund⁴, Sella Provan⁴, Tore Kvien⁵ and Daniel Aletaha⁶, ¹Medical University of Vienna, Wien, Austria, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria
Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
Abstract Number: 0159 • ACR Convergence 2023
Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Krati Chauhan¹, Steven Scaife² and Michael Buhnerkempe¹, ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Southen Illinois University - School of Medicine., Springfield, IL
Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
Abstract Number: 0161 • ACR Convergence 2023
Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Brigitte Michelsen¹, Mikkel Østergaard², Michael Nissen³, Adrian Ciurea⁴, Burkhard Moeller⁵, Lykke Ørnbjerg⁶, Jakub Zavada⁷, Bente Glintborg⁸, Alan MacDonald⁹, Karin Laas¹⁰, Dan Nordstrom¹¹, Bjorn Gudbjornsson¹², Florenzo Iannone¹³, Pasoon Hellamand¹⁴, Tore Kvien¹⁵, Ana Maria Rodrigues¹⁶, Catalin Codreanu¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Johan Karlsson Wallman²⁰, Jiri Vencovsky²¹, Anne Gitte Loft²², Maureen Heddle²³, Sigrid Vorobjov²⁴, Anna-Mari Hokkanen²⁵, Gerdur Maria Grondal²⁶, Marco Sebastiani²⁷, Marleen van de Sande²⁸, Eirik Kristianslund²⁹, Maria Jose Santos³⁰, Corina Mogosan³¹, Matija Tomsic³², Jose Federico Diaz-Gonzalez³³, Daniela Di Giuseppe³⁴ and Merete Hetland⁶, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ³Geneva University Hospitals, Geneva, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁹NHS Grampian, Aberdeen, United Kingdom, ¹⁰Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ¹⁷Center for Rheumatic Diseases, Bucharest, Romania, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lund University and Skåne University Hospital, Lund, Sweden, ²¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²²Aarhus University, Horsens, Denmark, ²³Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ²⁴National Institute for Health Development, Tallinn, Estonia, ²⁵Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁶Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²⁷Azienda Policlinico di Modena, Modena, Italy, ²⁸Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²⁹Diakonhjemmet Hospital, Oslo, Norway, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹University of Medicine and Pharmacy, Bucharest, Romania, ³²University Medical Centre Ljubljana; Universitiy of Ljubljana, Ljubliana, Slovenia, ³³Hospital Universitario de Canarias, La Laguna, Spain, ³⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…
Abstract Number: 0175 • ACR Convergence 2023
Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach
Ashkan Ara¹, Matthew Chenoweth¹ and Christopher Scannell², ¹University of California Los Angeles, Los Angeles, CA, ²UCLA / West Los Angeles VA Medical Center, Los Angeles, CA
Background/Purpose: Cost-related medication non-adherence (CRN) occurs when patients are unable to follow their prescribed medication regimen due to financial constraints, such as high costs or…
Abstract Number: 0177 • ACR Convergence 2023
Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities
Ashkan Ara¹, Matthew Chenoweth¹, Christopher Scannell² and John FitzGerald¹, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA / West Los Angeles VA Medical Center, Los Angeles, CA
Background/Purpose: Cost-related medication non-adherence (CRN), a measure of drug affordability, refers to a patient's inability to adhere to a prescribed medication regimen due to high…
Abstract Number: 0198 • ACR Convergence 2023
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
Stephen Lindsey¹, Brittany Hill², Sheela Sheth³ and Arya Loghmani², ¹LSU Health Science Center, New Orleans, LA, ²Louisiana State University, New Orleans, LA, ³Tulane University, New Orleans, LA
Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0465 • ACR Convergence 2023
The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists
Mehret Birru Talabi¹, Bonnie Bermas², Irene Blanco³, Ashira Blazer⁴, Megan Clowse⁵, Cuoghi Edens⁶, Leslie Pierce⁷, Catherine Wright¹ and Rosalind Ramsey-Goldman³, ¹University of Pittsburgh, Pittsburgh, PA, ²UT Southwestern, Dallas, TX, ³Northwestern University, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY, ⁵Duke University, Chapel Hill, NC, ⁶University of Chicago, Chicago, IL, ⁷University of Pittsburgh, Raleigh, NC
Background/Purpose: In June 2022, the U.S. Supreme Court's decision in Dobbs v. Jackson Women's Health removed the federal constitutional right to abortion, returning abortion policy…
Abstract Number: 084 • 2023 Pediatric Rheumatology Symposium
Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic
Kristiana Nasto¹, David McDonald¹, Kyla Fergason¹, Mary Robichaux¹, Bernard Danna¹, Monique Maher¹, Alexander Alexander¹, Danielle Guffey¹, Miriah Gillispie-Taylor² and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Transition of adolescents with chronic healthcare needs to adult care may result in poor outcomes. We have developed a program to improve the transition…
Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Kristin Wipfler¹, Adam Cornish¹, Rebecca Schumacher², Yomei Shaw³, Patricia Katz⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ⁴UCSF, San Rafael, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…
Abstract Number: 0227 • ACR Convergence 2022
The Rheumatology Workforce: Analyzing Geographic and Temporal Variations Among the Rheumatology Physician Workforce in the United States
Kavish Singh¹, Lynn Foster-Johnson², Sladjana Skopelja-Gardner³, Arabi Rasendrakumar⁴, Temitope Ajayi⁵ and Aakanksha Khanna⁶, ¹Montefiore Medical Center, Brooklyn, NY, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴University of Buffalo, Buffalo, NY, ⁵University at Buffalo, Buffalo, NY, ⁶Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: To analyze recent trends in the rheumatology workforce related to temporal and national geographic variation in the United States (US). Methods: The publicly available physician workforce…
Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Anna Montgomery¹, Gary Tarasovsky², Mary Whooley², Jennifer Barton³, Karla Miller⁴, Holly Mitchell⁵, Jo Dana², Kimberly Reiter⁶, Elizabeth Wahl⁷, Karine Rozenberg-Ben-Dror⁸, Jing Li⁹ and Gabriela Schmajuk¹⁰, ¹University of California San Francisco, Reno, NV, ²San Francisco VA Medical Center, San Francisco, CA, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴University of Utah Division of Rheumatology/VA Salt Lake City Health Care, Salt Lake City, UT, ⁵Ralph H. Johnson VA Hospital, Mount Pleasant, SC, ⁶Albuquerque VA Medical Center, Albuquerque, NM, ⁷VA Puget Sound Healthcare System, Seattle, WA, ⁸Greater Lakes Region/VISN 12 Dept Veterans Affairs, Hines, IL, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰UCSF / SFVA, San Francisco, CA
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…
Abstract Number: 0724 • ACR Convergence 2022
Development of a Global Strategy to Strengthen Health Systems for Prevention and Management of Musculoskeletal Health
Andrew Briggs¹, Anthony Woolf², Carmen Huckel Schneider³, Helen Slater⁴, Joanne Jordan⁵, Sakira Parambath⁶, James Young⁷, Saurab Sharma⁸, Deborah Kopansky-Giles⁷, Swatee Mishra⁹, Kristina Akesson¹⁰, Karsten Dreinhoefer¹¹, Neil Betteridge¹² and Lyn March¹³, ¹Curtin University, Perth, Western Australia, Australia, ²Bone and Joint Resaerch Group, Truro, United Kingdom, ³Menzies Centre for Health Policy and Economic, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ⁴Curtin School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia, ⁵HealthSense (Aust) Pty, Ltd, Melbourne, Australia, ⁶Menzies Centre for Health Policy and Economics, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ⁷Department of Research, Canadian Memorial Chiropractic College, Toronto, ON, Canada, ⁸Department of Physiotherapy, Kathmandu University School of Medical Sciences, Kavre, Nepal, ⁹Sydney Musculoskeletal, Bone and Joint Health Alliance. Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ¹⁰Department of Clinical Sciences Malmo, Clinical and Molecular Osteoporosis Research Unit, Lund University, Malmö, Sweden, ¹¹Medical Park Berlin Humboldtmühle, Berlin, Germany, ¹²Neil Betteridge Associates, London, United Kingdom, ¹³Sydney Medical School, Institute of Bone and Joint Research, and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: The need to control the burden of musculoskeletal (MSK) conditions is not reflected in policies and practices across the globe. This study aims to…
Abstract Number: 1194 • ACR Convergence 2022
Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
Jenny Gong¹, Emma Barnboym², megan O'Mara³, Natalie Gurevich³, Maya Mattar⁴, Donald Anthony⁵, Adam Perzynski² and Nora Singer⁶, ¹Case Western School of Medicine, Cleveland, OH, ²The MetroHealth System, Cleveland, OH, ³Cleveland Veteran Affairs Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Patients with autoimmune disease are at increased risk for complications from SARS-CoV-2 infection. We aimed to compare patient perspectives on COVID-19 vaccination among persons…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.